Matches in SemOpenAlex for { <https://semopenalex.org/work/W2358663119> ?p ?o ?g. }
Showing items 1 to 75 of
75
with 100 items per page.
- W2358663119 abstract "Background: There is no single antiviral drug that can eradicate the hepatitis B virus (HBV) infection. It has been shown in no vitro study that lamivudine (LMD) and panciclovir (the active metabolite of famciclovir, FCV) may act synergistically in inhibiting HBV replication. Aims: To study the therapeutic efficacy of combination of LMD and FCV in patients with chronic hepatitis B. Methods: Twenty-one patients with chronic hepatitis B, who had been given monotherapy of LMD for more than 6 months without improvement, all had increased serum alanine aminotransferase (ALT) and HBV DNA levels and positive HBsAg, and 17 of them had positive HBeAg. The diagnosis was verified by histology in 12 HBeAg-positive cases. All patients were given combination therapy with LMD (100 mg qd) and FCV (500 mg tid) orally for 4 months as a course of treatment, and then with LMD alone in the followed up period for 5-10 months. Results: Serum HBV DNA levels were 1×108.19±0.58 copies/ml before entry into the present trial, and decreased to 1× 104.55±1.18 copies/ml at the end of a course of treatment and 1× 105.25±1.82 copies/ml in the followed up period (P 0.01). ALT decreased to 79 U/L±50 U/L at the end of a course of treatment and 81 U/L±48 U/L in the followed up period from 225 U/L±110 U/L before the trial (P 0.01). In 17 patients with positive HBeAg, 8 (47.1%) had HBeAg/anti-HBe seroconversion with a significant decrease of HBV DNA ( 1×104 copies/ml) and normal ALT (P0.01). Among 4 patients with negative HBeAg, 3 had decrease of HBV DNA to below 1×104 copies/ml, associated with a significant decrease of ALT. Two patients had recurrent flares in followed up period, but both HBV DNA and ALT were lower than the pretreatment levels. In 10 patients who received the second liver biopsy, improvement of inflammatory activities and fibrosis were seen in 8 (80%) and 4 (40%) cases, respectively (P0.05). Conclusions: Combination of LMD and FCV has synergistic or additive anti HBV effects, and may be an alternative therapy for patients with active chronic hepatitis B." @default.
- W2358663119 created "2016-06-24" @default.
- W2358663119 creator A5078861367 @default.
- W2358663119 date "2001-01-01" @default.
- W2358663119 modified "2023-09-24" @default.
- W2358663119 title "Combination Therapy of Lamivudine and Famciclovir for Patients with Chronic Hepatitis B" @default.
- W2358663119 hasPublicationYear "2001" @default.
- W2358663119 type Work @default.
- W2358663119 sameAs 2358663119 @default.
- W2358663119 citedByCount "0" @default.
- W2358663119 crossrefType "journal-article" @default.
- W2358663119 hasAuthorship W2358663119A5078861367 @default.
- W2358663119 hasConcept C126322002 @default.
- W2358663119 hasConcept C159047783 @default.
- W2358663119 hasConcept C203014093 @default.
- W2358663119 hasConcept C2522874641 @default.
- W2358663119 hasConcept C2775940106 @default.
- W2358663119 hasConcept C2776543447 @default.
- W2358663119 hasConcept C2776723293 @default.
- W2358663119 hasConcept C2776999253 @default.
- W2358663119 hasConcept C2777333352 @default.
- W2358663119 hasConcept C2777382497 @default.
- W2358663119 hasConcept C2777410769 @default.
- W2358663119 hasConcept C2777869810 @default.
- W2358663119 hasConcept C2780593183 @default.
- W2358663119 hasConcept C3020491458 @default.
- W2358663119 hasConcept C55493867 @default.
- W2358663119 hasConcept C71924100 @default.
- W2358663119 hasConcept C86803240 @default.
- W2358663119 hasConcept C90924648 @default.
- W2358663119 hasConceptScore W2358663119C126322002 @default.
- W2358663119 hasConceptScore W2358663119C159047783 @default.
- W2358663119 hasConceptScore W2358663119C203014093 @default.
- W2358663119 hasConceptScore W2358663119C2522874641 @default.
- W2358663119 hasConceptScore W2358663119C2775940106 @default.
- W2358663119 hasConceptScore W2358663119C2776543447 @default.
- W2358663119 hasConceptScore W2358663119C2776723293 @default.
- W2358663119 hasConceptScore W2358663119C2776999253 @default.
- W2358663119 hasConceptScore W2358663119C2777333352 @default.
- W2358663119 hasConceptScore W2358663119C2777382497 @default.
- W2358663119 hasConceptScore W2358663119C2777410769 @default.
- W2358663119 hasConceptScore W2358663119C2777869810 @default.
- W2358663119 hasConceptScore W2358663119C2780593183 @default.
- W2358663119 hasConceptScore W2358663119C3020491458 @default.
- W2358663119 hasConceptScore W2358663119C55493867 @default.
- W2358663119 hasConceptScore W2358663119C71924100 @default.
- W2358663119 hasConceptScore W2358663119C86803240 @default.
- W2358663119 hasConceptScore W2358663119C90924648 @default.
- W2358663119 hasLocation W23586631191 @default.
- W2358663119 hasOpenAccess W2358663119 @default.
- W2358663119 hasPrimaryLocation W23586631191 @default.
- W2358663119 hasRelatedWork W13787941 @default.
- W2358663119 hasRelatedWork W2000923138 @default.
- W2358663119 hasRelatedWork W2020192045 @default.
- W2358663119 hasRelatedWork W2039218050 @default.
- W2358663119 hasRelatedWork W2044661401 @default.
- W2358663119 hasRelatedWork W207323148 @default.
- W2358663119 hasRelatedWork W2089667439 @default.
- W2358663119 hasRelatedWork W2258916498 @default.
- W2358663119 hasRelatedWork W2348750465 @default.
- W2358663119 hasRelatedWork W2348773495 @default.
- W2358663119 hasRelatedWork W2358555722 @default.
- W2358663119 hasRelatedWork W2363424319 @default.
- W2358663119 hasRelatedWork W2364650037 @default.
- W2358663119 hasRelatedWork W2366461110 @default.
- W2358663119 hasRelatedWork W2368455020 @default.
- W2358663119 hasRelatedWork W2377009965 @default.
- W2358663119 hasRelatedWork W2388230927 @default.
- W2358663119 hasRelatedWork W2388928938 @default.
- W2358663119 hasRelatedWork W2406005832 @default.
- W2358663119 hasRelatedWork W2410492417 @default.
- W2358663119 isParatext "false" @default.
- W2358663119 isRetracted "false" @default.
- W2358663119 magId "2358663119" @default.
- W2358663119 workType "article" @default.